|Bid||0.00 x 4000|
|Ask||0.00 x 4000|
|Day's Range||8.88 - 10.09|
|52 Week Range||3.55 - 12.44|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders will have a reason to smile today, with the analysts...
Joining me on the call today are Ryan Spencer, chief executive officer; Kelly MacDonald, chief financial officer; Robert Janssen, chief medical officer; and Donn Casale, senior vice president, commercial. Before I begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, its potential to become the standard of care and for universal recommendation.
Who wouldn't love a stock that has more than doubled in a little over five months? That's exactly what Dynavax Technologies (NASDAQ: DVAX) has done, thanks partially to good news in April for its COVID-19 vaccine partner Valneva.